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and followed prospectively until the endpoint of death or cardiac transplant. Genotyping 
for the ACE D and eNOS T alleles was done by standard techniques. Kaplan-Meier 
event free survival was first separately compared based on the presence or absence of 
ACE D or eNOS 1". For combined assessment, patients were grouped on the basis of 
having both ACE D and eNOS T(n=209), either ACE D or eNOS T(n=222), or neither 
(n=32). 
Results: 377 patients (81%) had at least one copy of the ACE D allele, while 86 (19%) 
were II. For ordered ACE genotype (DD/DI/II), the D allele was associated with poorer 
event free survival(p=O.03). The relative risk (RR)of death or transplant for patients with 
at least one D allele (DD or DI versus II) was 1.41,95% confidence intervals (CI) 0.96 to 
2.08, p=0.08. For eNOS T allele, 263 (57%) had at least one copy, which was associated 
with poorer event free survival (p=0.03), and an increased RR o1 events (RR= 1.37, 95% 
CI 1.02 to 1.84, p=0.035. When data was combined, the effects on RR appeared inde- 
pendent and additive. Compared to patients with neither, the RR of events patients with 
both ACE D and eNOS was 2.02 (95%CI 1.02 to 4.00, p=0.04). Patients with both eNOS 
T and ACE D had significantly poorer transplant-free survival (1 year % survival for nei- 
ther/one/both variants= 87/82/75; 2 year 74/73/62, p=0.003). 
Conclusion: Combining ACE and eNOS genotype information increases the power of 
genetic risk stratification for patients with congestive heart failure. Thus, polygenic risk 
assessment using multiple genes may be a superior prognostic tool to single gene analy- 
sis in heart failure patients. 
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and  Heart  Fa i lure 
Melissa J. Bvrne, David Kaye, Murray Esler, John M. Power, Baker Medical Research 
Institute, Melbourne, Australia. 
Background: Atrial fibdllation (AF) is associated with increased risk of ventdcutar pump 
failure death in patients with ventdcular systolic dysfunction. We studied the mechanisms 
of the apparent synergistic relationship of AF with moderate heart failure (mod HF). 
Methods: Sixteen sheep were rapid paced for 21 days (rnod HF). Chronic AF was initi- 
ated in 8 of these animals at 14 days (rnod HF + AF). All animals were atrial defibrillated 
at 21 days (rnod HF/defib or mod HF + AF/defib). Left ventricular end diastolic pressure 
(LVEDP) and ± dP/dt were determined during exercise, and coronary sinus noradrena- 
fine (CS NA) determined at rest. 
Results: LVEDP was significantly reduced in animals with rnod HF + AF compared to ani- 
mals with rnod HF alone. Defibrillation of AF increased LVEDP to levels observed in rood 
HF alone within 24 hours. AF significantly reduced + dP/dt in rnod HF animals which 
improved after defibrillation. CS NA was significantly raised in mod + AF animals com- 
pared to rnod HF alone and reversed following defibrillation. 
Conclusion: Concomitant AF in this ovine model of rnod HF resulted in a significant 
decrease in cardiovascular function. Significantly higher cardiac levels of NA maybe one 
mechanism behind the synergistic relationship between AF and HF. 
LVEDP (mmHg) +dP/dt -dP/dt CS NA (pg/ml) 
at2Ominexercise at 20 min exercise at2Ominexercise atrest 
8.32± 2170± 
Bageline 2017 ± 119.20 220.34 ± 34.98 
1.73 63.48 
20.74 ~: 1754 ± 
Mod HF 1609 ± 83.67a 247.78 ± 78.59 
4.15a 145.05a 
21.61 ± 1474 ± 
Mod HF/defib 1446 ± 94.77a 290.14 ± 91.66 
4.07a 96.58a 
13.44± 1133± 
Mod HF+ AF 1122 ± 121,61a 530.10 ± 79.42a 
3.03b 86.94ab 
23.05 ± 1414 ± 
Mod HF + AF/defib 1266 ± 114,88a 244.76 ± 20.87c 
3.48ac 115.97ac 
a - signif.diff rom baseline, b - signif, diff from mod HI=, 
c - signif, diff from mod HF + AF 
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MecGowan, Michael A. Mathier, Sdnivas Murali, Karen Janosko, Arthur M. Fetdman, 
Barry London, Dennis M. McNarnara, University of Pittsburgh Medical Center, Pittsburgh, 
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Background:For patients with congestive heart failure, the Ile164 variant of the 62 edr- 
energic receptor associated with decreased receptor function has been reported to 
adversely influence transplant-free survival. The impact of beta blocker therapy on this 
genetic risk remains unknown. We examined this question in a single center prospective 
study of Genetic Risk Assessment of Cardiac Events (GRACE) for patients with conges- 
tive heart failure. 
Methods:Four-hundred and fifty-eight patients (mean age 55.7 + 11.9, 48% ischernic, 
71% male) referred with heart failure to the Cardiornyopathy Clinic at the University of 
Pittsburgh with an LVEF _< 0.45 were enrolled in the study. At the time of enrollment blood 
was obtained for DNA analysis and detailed information about medical therapy was 
recorded. Patients were then followed prospectively towards an endpoint of death or 
transplantation. Patients were genotyped for the Thr16411e polyrnorphisrn using standard 
PCR based techniques. 
Results: Thirteen patients (2.8%) were heterozygous for the 164 variant, and the 
remainder were homozygous for Thr164. No Ile164 homozygotas were identified. Beta 
blocker therapy was similar in both groups (39% vs. 43%). Patients with the Ile164 vari- 
ant had a poorer transplant-free survival (1 year transplant-free survival, 61% vs. 81%, 
p=0.04). This effect was primarily evident in patients not on beta blocker therapy (1 year 
event-free survival, 33% vs. 77%, p=0.003). Overall, of patients with Ile164 not on beta 
blockers, 7/8 had events (3 transplants, 4 deaths) compared with 0/5 on beta blocker 
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therapy. 
Conclusion: Consistent with previous reports, this data suggests the Ile164 variant of 
the 62 adrenergic.receptor adversely affects heart failure survival. It appears, however, 
that this effect may be modulated by beta blocker therapy. The impact of beta blocker 
therapy on this genetic risk requires further investigation in a larger prospective study. 
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Stanford Universi~ Stanford, California. 
Backgrounc~ The impact of angiotansin-converting enzyme (ACE) gene polymorphisrn 
on neurohormonal responses following high- versus low-dose ACE inhibitor therapy is 
unclear. 
Methods: ACE Insertion (I) or Deletion (D) genotype was determined in 74 patients with 
chronic heart failure (mean age 51+12 years, mean LVEF 21+8%, NYHA Ill-IV) using 
polymerase chain reaction. Patients were randomized to receive either high-dosa (40rag/ 
day, n=37) or low-bose (5rng/day, n=37) enalapril over 6 months. Monthly pre-enalapril 
(trough) and post-enalapdl (peak) neurohormonal evels, including serum ACE activity 
(sACE), serum angiotensin II (A-II), plasma renin activity (PRA) and plasma aldosterone 
(ALDO), were compared between subgroups of patients with D/D, I/D and I/I genotypes, 
and between high- and Iow-dosa within each genotype subgroup using ANOVA. 
Results: Observed frequencies of the D/D(n=23), I/D(n=35) and I/1(n=16) genotypes did 
not differ significantly between high- and low-dose groups. At baseline, peak/trough 
sACE and peak PRA were significantly higher in the D/D genotype. However, only trough 
sACE was consistently higher in the D/D genotype when compared to the liD and I/I gen- 
otypes throughout he study (p<0.05). Within each genotype subgroup, although there 
were no significant differences in trough sACE between baseline and end of study, peak 
sACE demonstrated a dose-dependent reduction in all 3 genotypes at end of study 
(p<0.05). Peak and trough ALDO and A-II did not differ significantly between the 3 geno- 
types throughout he 6-month course, nor between high- and low-closes within each gen- 
otype subgroup. At the end of study, ALDO escape (2160 pg/rnL) and A-II reactivation 
(_>10.1 pg/mL) were observed in 35% and 85% of subjects respectively, and was not 
affected by ACE genotype nor enalapril dosage. 
Conclusion: Consistent with previous reports, sACE was consistently higher in the D/D 
genotype when compared to I/D or I/I subgroups. A dose-dependent reduction in peak 
sACE was observed in all 3 genotypes at the end of study. This study could not demon- 
strate a difference in ALDO and A-II suppression between different ACE genotypes, nor 
between high- and low-bose enalapril within each genotype subgroup. 
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1038-146 Histologic Findings in Pat ients  With Cl in ica l  and  
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Cristina Chirnenti. Maurizio Pieroni, Retains Verardo, Attilio Massri, Andrea Frustaci, 
Catholic University, Rome, Italy. 
Background: The value of endornyocardial biopsy compared with other non-invasive and 
invasive cardiac exams in the diagnosis of arrhythmogenic right ventdcular dysplasia 
(ARVD) is still controversial. We report the biventricular histologic findings of 30 patients 
(pts) with a diagnosis of ARVD established by applying the conventional clinical and 
instrumental criteria. 
Methods: Among 78 consecutive pts with ventdcular arrhythmias, normal left ventdcular 
(LV) global function and coronary arteries, 30 (38 %) had arrhythrnias with left bundle 
branch block morphology and right ventricle (RV) abnormalities. All tots underwent non 
invasive (2D-echo, magnetic resonance) and invasive cardiac studies (including LV, RV 
angiography with biventricular endomyocardial biopsy and electrophysiologic study). 
Endornyocardial biopsies were performed in the septat-apical region of the LV and in 
specific sites of the RV (i.e. apex, anterior free wall, inferior wall). On the basis of electro- 
cardiographic, arrhythmic and morpho-functional cdteria all pts would have received the 
diagnosis of ARVD. 
Results: At histology, the diagnosis of ARVD was confirmed only in 9 pts, while in 21 pts 
a focal inflammatory infiltrate with necrosis of the adjacent myocytes diagnostic for rnyo- 
cardifis was present in alI,RV specimens and even in the LV biopsies from 10 pts. No 
fatty tissue infiltration was observed in rnyocarditic pts, while loci of inflammatory cells 
were present both in the RV and LV of 4 pts with ARVD. No statistically significant differ- 
ence was found between pts with ARVD and with rnyecarditis regarding the severity of 
ventricular arrhythmias (p=0.9359), ECG depolarization and repoladzation abnormalities 
(p--0.92), structural RV abnormalities, including global or regional RV dilatation 
(p=0.8731) and dysfunction (p=0.8731). Finally, magnetic resonance imaging showed 
the typical signal of high intensity in T1 weighted images in 66 % of ARVD pts and in 62% 
of rnyocardific pts (p=0.8687). 
Conclusions: An elective RV rnyocarditis can mimic an ARVD. Histology seems the more 
correct diagnostic tool with significant impact on prognosis and treatment. 
